Stocks · News reference
Mirum Pharmaceuticals (NASDAQ:MIRM) reported quarterly losses of $(1.06) per share which missed the analyst consensus estimate of $(0.68) by 55.88 percent. This is a 783.33 percent decrease over losses of $(0.12) per
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Citizens analyst Jonathan Wolleben reiterates Mirum Pharmaceuticals (NASDAQ:MIRM) with a Market Outperform and maintains $137 price target.
Read original at benzingaTD Cowen analyst Joseph Thome maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and lowers the price target from $145 to $140.
Read original at benzingaRBC Capital analyst Lisa Walter maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and lowers the price target from $148 to $135.
Read original at benzingaCitizens analyst Jonathan Wolleben maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Market Outperform and lowers the price target from $146 to $137.
Read original at benzinga